Target
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
Ligand
BDBM50579531
Substrate
n/a
Meas. Tech.
ChEMBL_2135438 (CHEMBL4845048)
IC50
2.6±n/a nM
Citation
 Turdi, HChao, HHangeland, JJAhmad, SMeng, WBrigance, RZhao, GWang, WMoore, FYe, XYMathur, AHou, XKempson, JWu, DRLi, YXAzzara, AVMa, ZChu, CHChen, LCullen, MJRooney, SHarvey, SKopcho, LPanemangelor, RAbell, LO'Malley, KKeim, WJDierks, EChang, SFoster, KApedo, AHarden, DDabros, MGao, QPelleymounter, MAWhaley, JMRobl, JACheng, DLawrence, RMDevasthale, P Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. J Med Chem 64:14773-14792 (2021) [PubMed]  Article
Target
Name:
Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
Synonyms:
2.4.1.143 | Beta-1,2-N-acetylglucosaminyltransferase II | GNT-II | GlcNAc-T II | MGAT2 | MGAT2_HUMAN | Mannoside acetylglucosaminyltransferase 2 | Monoacylglycerol acyltransferase 2 (MGAT2) | Monoacylglycerol acyltransferase type 2 (h-MGAT2) | N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase II | h-MGAT2 (human monoacylglycerol acyltransferase type 2)
Type:
n/a
Mol. Mass.:
51567.80
Organism:
Homo sapiens (Human)
Description:
Q10469
Residue:
447
Sequence:
MRFRIYKRKVLILTLVVAACGFVLWSSNGRQRKNEALAPPLLDAEPARGAGGRGGDHPSVAVGIRRVSNVSAASLVPAVPQPEADNLTLRYRSLVYQLNFDQTLRNVDKAGTWAPRELVLVVQVHNRPEYLRLLLDSLRKAQGIDNVLVIFSHDFWSTEINQLIAGVNFCPVLQVFFPFSIQLYPNEFPGSDPRDCPRDLPKNAALKLGCINAEYPDSFGHYREAKFSQTKHHWWWKLHFVWERVKILRDYAGLILFLEEDHYLAPDFYHVFKKMWKLKQQECPECDVLSLGTYSASRSFYGMADKVDVKTWKSTEHNMGLALTRNAYQKLIECTDTFCTYDDYNWDWTLQYLTVSCLPKFWKVLVPQIPRIFHAGDCGMHHKKTCRPSTQSAQIESLLNNNKQYMFPETLTISEKFTVVAISPPRKNGGWGDIRDHELCKSYRRLQ
  
Inhibitor
Name:
BDBM50579531
Synonyms:
CHEMBL4869563
Type:
Small organic molecule
Emp. Form.:
C26H24F7N5O2
Mol. Mass.:
571.4899
SMILES:
Cc1ccc(cc1)C1=C(c2nnn[nH]2)C(=O)N[C@@](C1)(c1ccc(OCCCCCC(F)(F)F)cc1F)C(F)(F)F |r,c:8|
Structure:
Search PDB for entries with ligand similarity: